The direct compression route for 2-(4-bromomethyl)phenylpropionic acid pharma grade API is screened under low-moisture conditions because the free carboxylic acid and the aryl bromomethyl substituent both respond to ambient humidity. The API is pre-sieved through a 500 µm stainless steel screen and, if needed, air-jet milled to a d50 between 75 µm and 150 µm. A starting process formula of 20 wt% API, 73 wt% microcrystalline cellulose, 5 wt% croscarmellose sodium, 1 wt% colloidal silicon dioxide, and 1 wt% sodium stearyl fumarate is used as a development baseline; this is not an approved formula and the exact ratio is adjusted by compaction simulation and blend uniformity data. The mixture is blended in a bin blender at 55% to 65% fill volume for 15 minutes to 25 minutes, then lubricated for a separate 3 minutes to 5 minutes to avoid over-lubrication. Tablets are compressed on a rotary press with a forced feeder speed of 20 rpm to 25 rpm; hardness is maintained between 60 N and 90 N, and ejection force is recorded to detect punch binding. Disintegration is tested in 900 mL water at 37 ± 2 °C using USP Chapter 701, and dissolution is tested using USP Chapter 711 Apparatus II at 50 rpm or 75 rpm in a medium selected from pH 1.2, 4.5, or 6.8 solubility screening. The finished dosage form is a film-coated immediate-release tablet; coating is conducted with a low-moisture aqueous dispersion or non-aqueous system to avoid exposing the bromomethyl function to prolonged water contact. Batch failures on direct compression are typically caused by hopper segregation of the API rather than chemical degradation, especially at press speeds above 60% of maximum; in-line near-infrared monitoring of blend potency is used to identify and reject segregated portions before compression.

What Particle Size Control Is Needed Before Roller Compaction for High-Dose Tablets?

Roller compaction becomes necessary when dose loading exceeds 40 wt% or when flow through the press hopper falls below acceptable limits. The API is first analyzed by laser diffraction according to USP Chapter 429; if d50 is above 75 µm, particle size is reduced by air-jet milling before dry mixing with microcrystalline cellulose and crospovidone. The blend is compacted on a roller compactor with knurled or smooth rolls at a roll force of 4 kN/cm to 10 kN/cm, a roll gap of 1.5 mm to 2.5 mm, and a roll speed of 5 rpm to 15 rpm. Ribbon density is measured by envelope density or helium pycnometry; ribbons with density below 1.1 g/mL are rejected as a development criterion because they produce weak granules and capping tablets. The milled granules are screened through a 1.0 mm or 1.25 mm oscillating screen at low rotor speed, then blended with extragranular disintegrant and lubricant. The final tablet blend may contain 40 wt% to 60 wt% API, but the exact loading is determined by ribbon porosity and granule compressibility. Tablets are compressed to 70 N to 120 N hardness because roller compaction granules often require higher compaction force than direct compression powders. Uniformity of dosage units and dissolution follow USP Chapter 905 and USP Chapter 711; published dissolution data for this specific API are limited, so pH-solubility screening in 1.2, 4.5, and 6.8 media must be completed before a specification is fixed. The end product is a high-dose immediate-release tablet with compaction behavior dependent on roll force, ribbon porosity, and post-milling granule density.

Because high-shear wet granulation brings the bromomethyl group into contact with solvent, the process is run with a hydroalcoholic binder system and a closely controlled granulation endpoint. The API is dry mixed with lactose monohydrate, maize starch, and crospovidone in a high-shear granulator with bottom drive impeller and side chopper. The binder is an ethanolic povidone K30 solution; water comprises no more than 20% of the solvent mass to limit hydrolysis of the aryl bromomethyl substituent. The endpoint is detected by impeller torque and chopper amperage; the endpoint is reached when impeller torque rises by 30% to 40% from the dry-mix baseline. The wet mass is discharged and dried in a fluid-bed dryer at an inlet air temperature not exceeding 50 °C; product temperature is kept below 40 °C to avoid discoloration and loss of the bromomethyl group. Residual ethanol is tested according to USP Chapter 467 and ICH Q3C, with a target below 5000 ppm per day for ethanol. Dried granules are milled through a 1.0 mm screen, lubricated, and compressed into tablets with a granule fraction containing 30 wt% API; extragranular crospovidone is added before final blending. The finished product is an immediate-release tablet with release behavior governed by granule porosity, starch disintegrant performance, and the absence of hard over-granulated agglomerates. Batch-to-batch variance in granule bulk density is controlled by fixing impeller speed, binder addition rate, wet massing time, and drying air flow; a shift in granule density beyond 10% from the established band triggers rework or rejection because it alters tablet disintegration and dissolution.

Low-dose capsule filling and blend uniformity controls for the bromomethyl-substituted free acid

Low-dose capsule filling is performed on an automatic capsule machine with dosator or tamping-pin units. For strengths below 10 mg API, the drug substance is first triturated with a portion of microcrystalline cellulose or pregelatinised starch in a geometric dilution sequence; direct addition to the full diluent charge produces unacceptable blend uniformity. The final powder bed is conditioned to a bulk density of 0.45 g/mL to 0.65 g/mL and a tapped density above 0.70 g/mL; the Carr index is kept below 25 according to USP Chapter 616. The capsule filling environment is maintained below 40% RH because the free acid and bromomethyl group are moisture-sensitive and may form agglomerates. Hard gelatin capsules are filled only when shell moisture is below 13%; if the filling suite cannot maintain this condition, HPMC capsules are substituted to avoid shell brittleness and cross-linking. Blend uniformity is evaluated using USP Chapter 905 on 10 units from the beginning, middle, and end of the run; the acceptance value is set at 15.0 or tighter. The end product is a hard-shell capsule containing a powder blend of API, lactose monohydrate, croscarmellose sodium, and magnesium stearate; dissolution is measured using USP Chapter 711 Apparatus II with sinkers because capsule contents occasionally form a non-disintegrating plug. The main failure mode at scale is segregation of low-dose API fines at the top of the powder bed when machine speed exceeds 60% of nominal capacity; this is controlled by reducing vibration, maintaining hopper fill above 30%, and adjusting feed shoe contact pressure.

When Sterile Injectable Solutions Demand Non-Nucleophilic Buffers and pH Control

When a sterile injectable solution is required, the free acid is converted to its sodium salt with sodium hydroxide in Water for Injection, but the target pH must balance salt solubility against the degradation rate of the bromomethyl group. The bromomethyl carbon is electrophilic and reacts with nucleophilic species; Tris, ammonia, primary and secondary amines, and sulfites are excluded from the buffer system. Phosphate or citrate buffers at low concentration may be screened, but buffer capacity above 10 mM should be justified by stability data because the ionic strength can affect hydrolysis kinetics. The target pH is evaluated between 4.0 and 7.0; published data for this specific compound in parenteral solution are limited, so a forced degradation study with pH, temperature, dissolved oxygen, and light as factors is required before specification setting. The solution is passed through a 0.22 µm sterilising-grade membrane, filled into Type I borosilicate glass vials in an ISO 14644 Class 5 environment, and stoppered under aseptic conditions according to EU GMP Annex 1 and 21 CFR 211.67. Terminal sterilization is evaluated only after confirming that the bromomethyl moiety survives the selected cycle; otherwise aseptic filtration is used. Quality tests include sterility per USP Chapter 71, bacterial endotoxin per USP Chapter 85, particulate matter per USP Chapter 788, and visible particulates per USP Chapter 790. Elemental impurity limits are set following ICH Q3D based on the intended daily dose. Because aqueous exposure may convert the bromomethyl group to the corresponding hydroxymethyl derivative, the degradation product must be identified and controlled according to ICH Q3B thresholds. The end product is a sterile solution in sealed vials or ampoules; the unknown degradation product limit is set below 0.5% unless toxicological qualification supports a higher value. A lyophilized formulation is often preferred over this route when long-term stability data show a pH- and temperature-dependent increase in hydrolytic degradation.

For parenteral presentations where the aqueous solution route fails stability criteria, the API is lyophilized as a sterile cake. The pre-lyophilization solution is prepared at 5 mg/mL to 20 mg/mL in a vehicle containing mannitol or glycine as the bulking agent; the pH is adjusted to a non-nucleophilic buffer range, and sodium chloride is avoided in primary drying because it depresses the collapse temperature. The solution is filtered through a 0.22 µm membrane and filled into Type I glass vials with partial stopper closure. Freezing is performed with a shelf temperature of -40 °C to -50 °C; the freezing rate is controlled to produce a uniform ice structure. Primary drying is run at a shelf temperature of -20 °C to -10 °C and a chamber pressure of 50 mTorr to 150 mTorr; product temperature must remain below the collapse temperature. Secondary drying is conducted at 20 °C to 30 °C until Karl Fischer residual moisture is below 1.0 wt% according to USP Chapter 921. The endpoint is confirmed by differential pressure or moisture monitoring, not by a fixed drying time. The dried cake is inspected for meltback, cracking, and discoloration; cracked cakes are rejected because they indicate overly aggressive primary drying. Reconstitution time with Water for Injection is recorded as an internal process indicator; a target of 3 minutes is typical but is not an official specification. The lyophilized drug product is tested for sterility per USP Chapter 71, endotoxin per USP Chapter 85, particulate matter per USP Chapter 788, and residual moisture. The end product is a sterile lyophilized powder or cake for injection after reconstitution; stability studies must include an assay for the intact bromomethyl derivative and the corresponding hydroxymethyl hydrolysis product.

Granule growth and drying limits separate acceptable oral sachet batches from rejected product

Oral granules for sachet filling are produced by wet granulation followed by extrusion-spheronization or by high-shear granulation with controlled liquid addition. The granulation liquid is an ethanolic or hydroalcoholic solution of povidone or hydroxypropylcellulose; water is limited to reduce bromomethyl hydrolysis, and residual ethanol is controlled by ICH Q3C after drying. The wet mass is extruded through a 0.8 mm screen and spheronized at 800 rpm to 1200 rpm on a radial plate spheronizer. The granules are dried in a fluid-bed dryer with inlet air not exceeding 45 °C until loss-on-drying is below 1.5 wt%. After drying, the granule fraction between 0.5 mm and 1.2 mm is collected for packaging; undersize fines are recycled or discarded because they cause dissolution variability. Fill weight variation of sachets is controlled by net weight checks at line speed, and content uniformity of the active in the granule blend is verified by HPLC with acceptance limits based on pharmacopeial solid oral dosage requirements. Dissolution is measured using USP Chapter 711 with the sachet contents dispersed in the medium. The sachet may contain 250 mg to 1000 mg of API per unit depending on intended dose, but the labeled content is fixed by clinical or regulatory requirements rather than by a universal formula. The end product is a unit-dose oral granule in a sachet, either swallowed or dispersed in water before administration. The most common processing failure is granule attrition during packaging, which increases fines and creates dissolution failure; this is controlled by limiting drop height in the sachet filler and by using a low-moisture binder at a sufficient concentration to strengthen granules.

Controlling particle size and hydrolysis during oral liquid compounding

Oral liquid dosage forms based on 2-(4-bromomethyl)phenylpropionic acid are constrained by the same hydrolytic sensitivity observed in parenteral solutions. If an oral suspension is intended, the API is micronized by air-jet milling to a d90 below 20 µm to improve content uniformity and dissolution in the liquid vehicle. Excessive milling energy can create amorphous surfaces that absorb moisture and accelerate bromomethyl hydrolysis; therefore milling gas pressure and feed rate are controlled so that X-ray powder diffraction shows no more than 5% amorphous content. The micronized API is suspended in a non-nucleophilic vehicle containing sorbitol, microcrystalline cellulose/carboxymethylcellulose sodium, and polysorbate 80; the pH is maintained below 6.0 to slow bromide displacement. The suspension is filled into amber glass bottles with child-resistant closures, and storage temperature is assigned from real-time stability data. Preservative efficacy is tested according to USP Chapter 51, and deliverable volume is verified as part of the finished product specification. The end product is an oral suspension or a dry powder for oral suspension reconstituted before use; for the dry powder form, the cap liner moisture barrier is critical to prevent gradual hydrolysis of the bromomethyl group. Content uniformity of the suspension is established by weight or volume delivery rather than USP Chapter 905, because the latter applies to solid dosage units. The main boundary of this route is the hydrolytic instability of the bromomethyl group in aqueous media; the formulation must therefore avoid amine preservatives and high pH buffers.